2 min read

Anthem Biosciences Moat Analysis: Score & Risks

Moat Note · First-pass

Anthem Biosciences Ltd.

A first-pass moat teardown of Anthem Biosciences Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.

Moat & Margin16 Aug 2026 First-pass · ~3 min
5.12 / 10
NARROWProcess/Data-led

First-pass narrow read — primary edge in Intangible Assets. Provisional, single-pass evidence.

Provisional score · subject to modification based on new evidence

Anthem Biosciences Ltd. scores 5.12 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.

The teardown

Seven dimensions of moat

Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.

D5Intangible Assets6
M · Mechanism Verified verbatim

“We design processes to be patentable and scalable from the outset.”

Anthem Biosciences Ltd. · Annual Report · p.30
D6Efficient Scale6
M · Mechanism Verified verbatim

“We can't go in there, like, Celltrion or Samsung and say will give us the project or even Lonza, a ready-made project because they have the capacity to support it. But all the Indian companies are in the same position.”

Anthem Biosciences Ltd. · Earnings Call · p.11
D3Cost Advantage5.7
M · Mechanism Verified verbatim

“So, structurally, we want to ensure that material margin continues to improve. On products as well, we want to have yield improvement; so that could benefit us as well as our customers.”

Anthem Biosciences Ltd. · Earnings Call · p.5
D2Switching Costs5
No verified filing quote surfaced for this dimension in the first-pass evidence sweep.
D4Price Discretion5
M · Mechanism Verified verbatim

“Absolutely. $100 would be a nice price. It's a dream.”

Anthem Biosciences Ltd. · Earnings Call · p.17
D1Network Effects4.5
M · Mechanism Verified verbatim

“this quarter, we saw our specialty ingredients business reporting a decline”

Anthem Biosciences Ltd. · Earnings Call · p.4
D7Counter-PositioningExcluded
Excluded for this archetype.
D8Ungoverned RiskUnscored · Layer 2.5

D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.

The barrier gate

The barrier gate — first-pass

Replication — can a rival copy it?6.0
How hard it is for a rival to copy the edge (first-pass estimate).
Bypass — can a rival route around it?6.0
How easily a rival can route around the edge (first-pass estimate).

Effective barrier 6 — at or above 6, consistent with a narrow read. First-pass estimate.

What would change our mind
  1. Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.

  2. The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.

  3. Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.

First-pass note — provisional single-pass MoatSCORE 6.0 read, not the full deep dive. Educational research, not investment advice; no buy/sell recommendation, no price target. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.